COVID-19 studies are our top priority.

For new and updated trial submissions, we are processing trials as quickly as possible and appreciate your patience. We recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR

Registration number
Ethics application status
Date submitted
Date registered
Date last updated
Type of registration
Prospectively registered

Titles & IDs
Public title
Evaluation of clinical performance of PureVision[Registered trade mark] contact lenses in conjunction with Biotrue[Trade mark] lens care solution
Scientific title
Prospective, open-label, daily wear study of PureVision[Registered trade mark] contact lenses in conjunction with Biotrue[Trade mark] lens care solution to evaluate product performance in terms of lens case contamination and ocular surface effects in both experienced and new contact lens wearers
Secondary ID [1] 253220 0
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
contact lens wear 258755 0
ocular comfort 258756 0
Condition category
Condition code
Eye 258903 258903 0 0
Normal eye development and function

Study type
Description of intervention(s) / exposure
This is a prospective, single group, daily wear (DW) study where 40 participants will wear PureVision[Registered trade mark] study lenses bilaterally on a daily wear (DW) basis in conjunction with Biotrue [Trade mark] solution for 3 months. There will be a minimum of 5 scheduled visits: baseline, 2 hour visit, 2 week visit, 1 month visit and 3 month visit. These visits will involve assessment of visual acuity, examination with a slit-lamp biomicroscope (a specialised microscope for viewing the eye) and assessment of ocular comfort using questionnaires employing a 1-10 numeric rating scale. Lenses will be worn a minimum of 5 days per week, and 6 hours on the day lenses are worn.
Intervention code [1] 257694 0
Treatment: Devices
Comparator / control treatment
The control for the outcomes of ocular surface effect, and contact lens contamination will be historical data ( Study ACTRN12610000348055). The method of analysis of contact lens cases will be as per historical control
Control group

Primary outcome [1] 259761 0
Ocular surface effetcs as assessed with a slit lamp biomicroscope, which is a specialised microscope to view the eye
Timepoint [1] 259761 0
2 hours after baseline and after 2 weeks, 1 month and 3 months of DW
Secondary outcome [1] 268523 0
Contamination rate of contact lens cases used with studied solution compared to historical data. The historical data consists of data collected from previous clinical trials run at the Institute for Eye Research from 2005-2009
Timepoint [1] 268523 0
1 month and 3 months

Key inclusion criteria
-Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent;
-Be at least 18 years old, male or female;
-Willing to comply with the wearing and clinical trial visit schedule as directed by the investigator;
-Have ocular health findings considered to be “normal” and which would not prevent the participant from safely wearing contact lenses;
-Is correctable to at least 6/12 (20/40) or better in each eye with contact lenses;
-May be experienced or inexperienced at wearing contact lenses.
Minimum age
18 Years
Maximum age
No limit
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
-Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses;
-Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants;
-Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the study;
Use of or a need for any systemic medication or topical medications which may alter normal ocular findings/are known to affect a participant’s ocular health/physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the study;
N.B.: Systemic antihistamines are allowed on an ‘as needed basis’, provided they are not used prophylactically during the trial and at least 24 hours before study product is used;
Eye surgery within 12 weeks immediately prior to enrolment for this trial;
-Previous corneal refractive surgery;
-Contraindications to contact lens wear;
-Known allergy or intolerance to ingredients in any of the study products;
-Currently enrolled in another clinical trial.
-Participation in a clinical trial within the previous 2 weeks for dispensing studies and 48 hours between in-house studies;

The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the study requirements, or if it is believed to be in the participant’s best interests.
*Formal testing of pregnancy is not required. A participant’s verbal report is sufficient.

Study design
Purpose of the study
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Particicpant needs to satisfy inclusion/exclusion criteria. All participants are allocated the same treatment
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)

Funding & Sponsors
Funding source category [1] 258167 0
Name [1] 258167 0
Brien Holden Vision Institute
Address [1] 258167 0
Level 5, Rupert Myers Building Gate 14, Barker Street University of New South Wales, NSW 2052
Country [1] 258167 0
Primary sponsor type
Other Collaborative groups
Abbott Medical Optics, Inc
1700 East St. Andrew Place
PO Box 25162
Santa Ana, CA 92799-5162, USA
United States of America
Secondary sponsor category [1] 257341 0
Name [1] 257341 0
Address [1] 257341 0
Country [1] 257341 0

Ethics approval
Ethics application status
Ethics committee name [1] 260154 0
VIHEC Human Research Ethics Committee
Ethics committee address [1] 260154 0
Level 4, North Wing, Rupert Myers Building (RMB), Gate 14, Barker Street, The University of New South Wales SYDNEY NSW 2052
Ethics committee country [1] 260154 0
Date submitted for ethics approval [1] 260154 0
Approval date [1] 260154 0
Ethics approval number [1] 260154 0

Brief summary
This study will examine the effect of a new solution on the ocular surface, subjective ratings of comfort and antimicrobial efficacy of the solution by lens-case examination. The hypotheses are these outcomes will be similar to historical control.
Trial website
Trial related presentations / publications
Public notes

Principal investigator
Name 31977 0
Mr Daniel Tilia
Address 31977 0
Level 5, North Wing, RMB, Gate 14, Barker Street, The University of New South Wales SYDNEY NSW 2052
Country 31977 0
Phone 31977 0
Fax 31977 0
Email 31977 0
Contact person for public queries
Name 15224 0
Mr Daniel Tilia
Address 15224 0
Level 5, North Wing, RMB, Gate 14, Barker Street, The University of New South Wales SYDNEY NSW 2052
Country 15224 0
Phone 15224 0
Fax 15224 0
Email 15224 0
Contact person for scientific queries
Name 6152 0
Mr Daniel Tilia
Address 6152 0
Level 5, North Wing, RMB, Gate 14, Barker Street, The University of New South Wales SYDNEY NSW 2052
Country 6152 0
Phone 6152 0
Fax 6152 0
Email 6152 0

No information has been provided regarding IPD availability
Summary results
Have study results been published in a peer-reviewed journal?
Other publications
Have study results been made publicly available in another format?
Results – basic reporting
Results – plain English summary